Literature DB >> 29429986

Comparison of photodynamic therapy and navigated microsecond laser for chronic central serous chorioretinopathy.

Cyprian Gabriel Ntomoka1, Bindu Rajesh2, Gachago Muchai Muriithi3, Abhilash Goud4, Jay Chhablani5.   

Abstract

OBJECTIVES: To compare the visual and anatomical outcomes after photodynamic therapy (PDT) and navigated microsecond laser (nMSL) for chronic central serous chorioretinopathy (CSCR).
METHODS: This retrospective study included eyes with chronic CSCR who underwent either PDT or nMSL with a minimum of 6 months' follow-up. Eyes with a history of treatment with any other modalities in the past or during 6 months post PDT or microsecond laser follow-up were excluded. Primary outcome measures included change in best-corrected visual acuity (BCVA) and central macular thickness (CMT). Secondary outcome measures included changes in subretinal fluid, hyper-reflective foci, cystic spaces, subfoveal choroidal thickness, and outer retinal structure integrity.
RESULTS: Forty-five eyes of 39 subjects (PDT group-23 eyes, nMSL group-22 eyes) with chronic CSCR were analyzed. At 6 months' follow-up, the nMSL group had significantly higher improvement in visual acuity compared to the PDT group (0.12 ± 0.24 vs -0.02 ± 0.20 (p = 0.039)). Reduction in central macular thickness was significantly higher in nMSL group compared to the PDT (85.5 ± 93.26 vs 24.47 ± 73.18 microns (p = 0.02)). Thirteen (59%) eyes in nMSL group had complete resolution of the SRF at 6 months compared to 5 (21.7%) eyes in PDT group. There was no significant difference in rest of the anatomical features between the groups.
CONCLUSIONS: nMSL seems to be superior over PDT in improving visual and anatomical outcomes at 6 months and can be considered as a cheap alternative to PDT in treatment of CSCR.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29429986      PMCID: PMC5997803          DOI: 10.1038/s41433-018-0029-z

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  32 in total

1.  Subretinal dot-like precipitates and yellow material in central serous chorioretinopathy.

Authors:  Ichiro Maruko; Tomohiro Iida; Akira Ojima; Tetsuju Sekiryu
Journal:  Retina       Date:  2011-04       Impact factor: 4.256

2.  Indocyanine green angiography of central serous chorioretinopathy.

Authors:  K Hayashi; Y Hasegawa; T Tokoro
Journal:  Int Ophthalmol       Date:  1986-04       Impact factor: 2.031

3.  Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification. ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group.

Authors: 
Journal:  Ophthalmology       Date:  1991-05       Impact factor: 12.079

4.  Safety enhanced photodynamic therapy with half dose verteporfin for chronic central serous chorioretinopathy: a short term pilot study.

Authors:  T Y Y Lai; W-M Chan; H Li; R Y K Lai; D T L Liu; D S C Lam
Journal:  Br J Ophthalmol       Date:  2006-04-05       Impact factor: 4.638

5.  Long-term chorioretinal changes after photodynamic therapy for chronic central serous chorioretinopathy.

Authors:  Helena Vasconcelos; Inês Marques; A Rita Santos; Pedro Melo; Isabel Pires; João Figueira; José Faria de Abreu; M Luz Cachulo; Rufino Silva
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-02-07       Impact factor: 3.117

6.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

7.  Subthreshold diode micropulse photocoagulation for the treatment of chronic central serous chorioretinopathy with juxtafoveal leakage.

Authors:  San-Ni Chen; Jiunn-Feng Hwang; Li-Fang Tseng; Chun-Ju Lin
Journal:  Ophthalmology       Date:  2008-12       Impact factor: 12.079

8.  Improvement in visual acuity and contrast sensitivity in patients with central serous chorioretinopathy after macular subthreshold laser therapy.

Authors:  Mehdi Behnia; Mehdi Khabazkhoob; Soheil Aliakbari; Arash E Abadi; Hassan Hashemi; Pupak Pourvahidi
Journal:  Retina       Date:  2013-02       Impact factor: 4.256

9.  Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients.

Authors:  Kishiko Ohkoshi; Tatsuo Yamaguchi
Journal:  Am J Ophthalmol       Date:  2009-10-28       Impact factor: 5.258

10.  Indocyanine green angiographic findings in central serous chorioretinopathy.

Authors:  C Prünte
Journal:  Int Ophthalmol       Date:  1995       Impact factor: 2.031

View more
  5 in total

1.  Comparison of the efficacy and safety of subthreshold micropulse laser with photodynamic therapy for the treatment of chronic central serous chorioretinopathy: A meta-analysis.

Authors:  Zhizhong Wu; Huixing Wang; Junsheng An
Journal:  Medicine (Baltimore)       Date:  2021-04-30       Impact factor: 1.817

2.  577 nm subthreshold micropulse laser treatment for acute central serous chorioretinopathy: a comparative study.

Authors:  He Long; Maoxiong Liu; Qinghua Hu; Xin Li
Journal:  BMC Ophthalmol       Date:  2022-03-05       Impact factor: 2.209

3.  Efficacy of nanosecond laser treatment in central serous chorioretinopathy with and without atrophy of retinal pigment epithelium.

Authors:  Hakan Kaymak; Saskia Funk; Andreas Fricke; Roxana Fulga; Karsten Klabe; Berthold Seitz; Achim Langenbucher; Hartmut Schwahn
Journal:  Int J Retina Vitreous       Date:  2020-06-04

Review 4.  Management of chronic central serous chorioretinopathy.

Authors:  Daren Hanumunthadu; Anna C S Tan; Sumit Randhir Singh; Niroj Kumar Sahu; Jay Chhablani
Journal:  Indian J Ophthalmol       Date:  2018-12       Impact factor: 1.848

5.  532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy.

Authors:  Keissy Sousa; Gil Calvão-Santos; Marina João; Nuno Gomes; Manuel Falcão
Journal:  Clin Ophthalmol       Date:  2020-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.